Similar articles

• Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants.

  Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM, DiNubile MJ; REST Study Team. Goveia MG, et al. Pediatr Infect Dis J. 2007 Dec;26(12):1099-104. doi: 10.1097/INF.0b013e31814521cb. Pediatr Infect Dis J. 2007. PMID: 18043445 Clinical Trial.
• Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

  Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. Vesikari T, et al. Vaccine. 2006 May 29;24(22):4821-9. doi: 10.1016/j.vaccine.2006.03.025. Epub 2006 Mar 31. Vaccine. 2006. PMID: 16621194 Clinical Trial.
• Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants.

  Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Bernstein DI, et al. J Infect Dis. 2002 Nov 15;186(10):1487-9. doi: 10.1086/344732. Epub 2002 Oct 22. J Infect Dis. 2002. PMID: 12404166 Clinical Trial.
• Rotavirus vaccines: recent developments and future considerations.

  Angel J, Franco MA, Greenberg HB. Angel J, et al. Nat Rev Microbiol. 2007 Jul;5(7):529-39. doi: 10.1038/nrmicro1692. Nat Rev Microbiol. 2007. PMID: 17571094 Review.
• Rotavirus vaccines: entering a new stage of deployment.

  Nakagomi O, Cunliffe NA. Nakagomi O, et al. Curr Opin Infect Dis. 2007 Oct;20(5):501-7. doi: 10.1097/QCO.0b013e3282a56ba0. Curr Opin Infect Dis. 2007. PMID: 17762784 Review.